Alkermes had its Relative Strength (RS) Rating upgraded from 66 to 73 Friday — a welcome improvement, but still short of the 80 or better score you look for.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Alkermes can continue to show renewed price strength and hit that benchmark.
Alkermes is building a consolidation with a 36.45 buy point. See if it can clear the breakout price in heavy volume.
The company reported negative growth for both the top and bottom lines last quarter. Alkermes is expected to release its next quarterly numbers on or around Jul. 23.
Alkermes earns the No. 32 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
